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Summary 
We did a cost-effectiveness analysis alongside a cluster-randomised trial of an 
intervention combining microfinance with gender and HIV training for the prevention of 
intimate-partner violence in South Africa. The average cost per client was $43 in the trial 
phase and $13 in the initial scale-up phase. On the basis of effect estimates from the 
trial, this translates to $711 and $213 per woman per IPV-free year gained. Using recent 
burden of disease estimates for intimate partner violence from South Africa, we 
estimated the cost per DALY gained as $7,700 for the trial and $2,307 for the initial 
scale-up. The findings were sensitive to the statistical uncertainty in effect estimates but 
otherwise robust to other key assumptions employed in the analysis. These estimates 
are probably conservative, as they do not include the health and development benefits of 
the intervention beyond IPV reduction. The findings suggest that this combined 
economic and health intervention was cost-effective in its trial phase and highly cost-
effective in scale-up.  
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Introduction 
 
Physical and sexual violence against women in South Africa is a major challenge, with 
recent estimates suggesting nearly 25% of ever-partnered women report having been in 
an abusive relationship 1. In addition to being an affront to women’s rights, intimate 
partner violence is increasingly recognised as a neglected but important public health 
problem, with significant impacts on women’s physical, reproductive and sexual, and 
mental health 2,3. The development of cost-effective interventions with the potential to 
prevent IPV and that are appropriate and relevant to resource poor settings, particularly 
in rural areas, remains an urgent priority. 
 
The Intervention with Microfinance for AIDS & Gender Equity (IMAGE) administered a 
package that combined microfinance with a participatory gender and HIV training 
curriculum to rural women in Limpopo Province, South Africa. Effects of the intervention 
were assessed by means of a cluster-randomised trial between 2001 and 2004. Effect 
estimates suggest that, relative to a matched comparison group, IMAGE participants 
experienced a 55% reduction in the past year experience of physical and/or sexual 
violence by an intimate partner (IPV) 5.   
 
The microfinance (MF) component of the intervention offered access to group-based 
credit and savings services, using a Grameen Bank model, 6 where five women formed a 
solidarity group to collectively guarantee one another’s loans. Forty women constituted a 
‘loan centre’ which met fortnightly to repay loans and discuss financial matters. The 
programme was administered by Small Enterprise Foundation (SEF, Tzaneen, South 
Africa) and was poverty focused – targeting the poorest households in each village 
identified through participatory wealth ranking techniques 7. Loans were used for income 
generation, with the most common types of businesses being buying and selling fruit and 
vegetables (54%), making/selling clothing (23%), food stalls (8%), and running small 
spaza shopsa (5%).  
 
                                                 
a These are small shops in the local village that sell a wide variety of products, ranging from bread and soft-drinks to small 
household wares.  
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The gender and HIV training component of the intervention was called Sisters for Life 
(SfL) and was implemented in each loan centre over a 12-15 month period. The 
curriculum was developed and piloted by a local and expatriate team over six months 
preceding its full implementation and evaluation. A key feature of this type of intervention 
was the upfront investment in capacity building. The SfL training curriculum comprised 
two phases 8. In phase 1, participants engaged in 10 one-hour training and discussion 
sessions at the beginning of compulsory fortnightly meetings. The training sessions used 
adult education techniques to address issues such as gender roles, cultural beliefs, 
relationships, communication, IPV and HIV.  In phase 2, those women identified by their 
peers as natural leaders were involved in an intensive one-week leadership training 
workshop. Upon returning to their communities, they in turn facilitated the development 
of village-level action plans geared towards individual and collective mobilisation around 
common concerns. These activities were repeated in the scaling up of the intervention 
following the completion of the trial. 
 
Many health problems, including IPV are deeply rooted in social and economic 
vulnerabilities. Proponents for integrating economic and health interventions argue that 
such packages provide both the means (income) and the knowledge (empowerment) to 
improve household well-being, and may serve as a stimulus for wider mobilisation 
around pervasive public health problems 4,9,10. Combined approaches such as IMAGE 
provide an incentive for individuals to participate in public health programs, which in the 
absence of loans, they likely would not. Furthermore, microfinance institutions contain an 
element of financial sustainability and, with 100 million clients worldwide 11, also work 
towards economies of scale – both critical for cost-effective interventions aimed at 
changing complex and deeply-rooted social norms 12.  Operational research into cost-
effective models of delivering public health interventions in resource poor settings that 
are both sustainable and scaleable remains at an early stage..  
 
In this paper, we assessed the cost-effectiveness of the IMAGE intervention in relation to 
its effect on IPV. As the microfinance component of the intervention package was 
financially sustainable and thus cost neutralb, we examined the incremental costs of 
integrating the training curriculum, alongside IPV-related outcomes and Disability 
                                                 
b Repayment rates by the end of the trial phase in the IMAGE sites were 99.7% and the host microfinance organisation, 
the Small Enterprise Foundation, was financially and operationally sustainable (expenses met by interest on loans).  
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Adjusted Life Years (DALYs). This enabled an assessment as to whether the type of 
activities incorporated in the approach can feasibly be built into the business models of 
microfinance organisations and importantly, whether such programs merit the allocation 
of scarce public funding through some form of subsidy. Finally, as access to the 
intervention in the post-trial period was substantially expanded and efforts were made to 
institutionalise the intervention within communities, we also examined the costs and 
cost-effectiveness of scale-up.  
 
Methods 
 
Trial costs were measured over the duration of the trial period during which the 
combined intervention package was delivered to 855 clients in four target villages. IPV 
outcomes were assessed after 2 years of intervention exposure. Costs associated with 
the scale-up were based on observed costs over the initial two years following the trial, 
and involved an additional 2598 clients. On the basis of the primary outcome of the trial, 
the costs of the intervention per additional woman free of IPV for the previous 12 months 
were estimated for both the trial and scale-up. These results were then transformed, on 
the basis of demographic 13 and burden of disease data from South Africa 14,15, into 
estimates of costs per DALY gained to enable a general assessment of cost-
effectiveness. The cost-effectiveness of IMAGE in the trial phase was thus estimated 
separately from the initial 2 years of scale-up. 
 
Costs 
 
The costing adopted an ingredients approach 16 based on the financial statements of the 
program and host microfinance organisation. All costs are reported in 2004 US dollar 
prices (US$1 = 6.45 ZAR). A provider perspective was adopted, and the costs to 
participants and families were not included in this analysis (e.g. travel and opportunity 
costs of attending meetings). A 3% discount rate was used throughout, as recommended 
by the World Health Organization 17. 
 
Insert table 1 
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All items of capital (office space, equipment, vehicles) were assigned a current 
market/replacement value based on national South African prices at the base year (e.g. 
the estimated local prevailing market rent for office space) and cost allocated to the 
intervention on the basis of estimated use. 
 
Personnel costs, valued either at prevailing gross salary in the relevant year or – for 
volunteer labour – at the market rates for equally qualified personnel occupying 
equivalent positions, reflecting their economic cost18.  Other recurrent costs included 
supplies, transport and maintenance. 
 
Costs associated with adherence to the research protocol were excluded 18,19. These 
were incurred because the sites chosen for the intervention were located substantially 
farther apart than would normally be the case due to random village assignment. 
Adjustments to transport costs were therefore made by assuming the use of public 
transport by local staff in line with program operations in a non-research setting. 
 
A major component of costs were the initial development costs associated with training 
of staff and production of training materials. As it was expected that the initial investment 
in these activities would yield benefits beyond the duration of the study, such costs were 
annuitised 16,20. Initial staff training was annuitised over 5 years, while conceptualisation 
of the protocol and production of the SfL training manuals was annuitised over 10 years 
to reflect their potential for use not only in scale-up but in other settings. Factored into 
these costs were consultancy services that were required for the planning of the initial 
intervention and in the training of staff and volunteers.  
 
At the commencement of scale-up, further training was undertaken to enable expansion 
of the program. Major new inputs were the training and deployment of additional 
facilitators. Each trainer was responsible for nine loan centres, in line with standard 
practice for the microfinance partner. The cost of this training was annuitised in line with 
the approach used at the outset of the trial. Overall, the analysis of scale-up costs 
employed similar assumptions and methods as for the trial.  
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Effectiveness  
 
The effectiveness of the intervention in terms of reduction in the risk of past year IPV as 
observed in the trial was assumed to apply to both the trial and the scale-up. Scale-up 
entailed the expansion of the intervention to populations in surrounding districts where 
we assumed the integrity and quality of the intervention was well-maintained. We would 
expect no difference in baseline characteristics between such similarly treatment-naïve 
trial and scale-up populations to thus suggest any difference in absolute effect. 
 
The transformation of the primary trial outcome into DALYs is outlined in table 1. It was 
based on recent burden of disease estimates of DALYs lost to IPV in South Africa 14,15 
and population data 13. It indicates that each case of a woman reporting an experience of 
IPV in the previous 12 months, on average, resulted in a loss of 0.0923 DALYs.  
 
Insert table 1  
 
Table 2 indicates the DALY loss from the specific conditions which were included as the 
relevant sequelae of IPV in the original burden of disease estimates. 15  
  
Insert table 2 
 
Sensitivity analysis was conducted in relation to the following parameters:  
• the upper and lower bound confidence limits of the effect estimates from the trial5  
• increasing the expected life of investment in staff training to 10 years; 
• decreasing the expected life of investment in protocol development and training 
manuals to 5 years; and 
• varying the discount rate to 0% and 6% 17. 
 
Results 
 
Development costs 
Table 3 sets out the development costs. These included the costs of training and training 
material development incurred initially, at the outset of the trial, and the further training 
costs at the commencement of the scale-up.   
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Insert table 3 
 
The initial training costs were $61,115, the costs of training material development were 
$13,877, and further training costs at scale-up were $57,663. A significant component of 
the development costs at the initiation of the trial were consultant fees paid to overseas 
experts; these were not incurred in the scale-up since the training in the latter phase was 
carried out by local program staff. 
 
Cost-effectiveness 
 
Table 4 reports a breakdown of cost figures for the duration of the trial and initial scale-
up and cost-effectiveness estimates.   
Insert table 4 
 
Over the two-year trial period, the cost of SfL training was $36,706. In total, 855 clients 
participated in the intervention, with total per client costs equal to $43. During the initial 
scale-up, the total cost to reach an additional 2,598 clients was $33,467, with a cost per 
client of $13. 
 
When set again effect estimates from the trial, cost-effectiveness ratios for the trial and 
the scale-up phase were $711 and $213 per woman per IPV-free year gained 
respectively. On the basis of the transformation outlined in table 1, these equate to 
$7,700 and $2,307 per DALY gained. 
   
Sensitivity analysis 
 
The sensitivity analysis in table 5 indicates:   
• some uncertainty in relation to the effect estimates – a consequence of the 
limited number of clusters enrolled in the trial, resulting in wide confidence 
intervals for most indicators. For the trial, the cost per DALY ranged from $5,500 
to $47,058; whilst for initial scale-up, it ranged from $1,648 to $14,099. 
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• the results were fairly robust in relation to the other parameters. Varying these 
results in cost-effectiveness between $5,015 to $8,193 for the trial phase and 
$1,454 and $2,503 for the initial scale-up. 
 
Insert table 5 
 
 
Discussion 
 
The IMAGE intervention combined group-based microfinance with a gender and HIV 
training program. During the trial period, the intervention reached 855 women in 12 loan 
centres from four study villages. The incremental cost of delivering the intervention 
during this phase was $36,706, or $43 per client. An assessment of the costs of taking 
this to scale within the local area showed that at two years, with coverage extended to a 
further 2,598 clients, there was a reduction in average costs to $13 per client. This 
indicates that substantial improvements in cost-effectiveness could be achieved with 
scaling-up. 
 
Within study villages, effect estimates suggest that levels of IPV would be reduced by 
55%, at an estimated cost-effectiveness of $7,700 per DALY gained in the trial phase 
and $2,307 per DALY gained in the initial 2 years of scale-up. There is little basis for 
direct comparison of these results as few previous intervention studies have 
demonstrated reductions in levels of IPV. Violence clearly has a number of potential 
‘down-stream’ consequences – from loss of life, physical disability and hospitalisation, to 
HIV infection 21, and emotional and psychological conditions including depression and 
anxiety (see table 3). Data on savings to the health sector associated with improvements 
in outcomes were not collected. While inclusion of such data would further support the 
case for cost-effectiveness, access to care for victims of IPV remains a serious obstacle 
in this population. 22. Nevertheless, generating estimates of disability-adjusted-life year 
(DALYs) attributable to IPV enabled the broader implications of violence to be factored 
into the assessment of outcomes in the economic evaluation.  
 
The World Health Organization generalised benchmark for cost-effectiveness is that a 
cost per DALY of less than 3 times the gross domestic product per capita (GDP) is 
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deemed ‘cost-effective’; and that a cost per DALY of less than the GDP per capita is 
deemed ‘highly cost-effective’23. In 2004, the GDP per capita in South Africa was $4,666 
24, indicating that the IMAGE intervention achieves cost-effectiveness in its trial phase 
and is highly cost-effective when scaled-up.  
 
Additionally, it needs to be recognised that complex structural interventions such as 
IMAGE have the potential to influence multiple health and social outcomes.  In such 
cases, cost-effectiveness might be more appropriately assessed through a cost-
consequences analysis in which the full range of benefits of the intervention are 
acknowledged 18,20,25. In the trial, it was established that the intervention reduced 
poverty, led to positive shifts in social capital and multiple indicators of empowerment, 
and resulted in lower levels of HIV risk behaviour among young women who received the 
intervention 4,5,26,27. As such, the cost per DALY estimates presented here based solely 
on reductions in IPV are likely to underestimate the true value of the intervention.  
 
There are also potential limitations to our estimates that are important to underscore. 
First, the distinction between research-driven costs and operational costs were at times 
complex to disentangle. Close collaboration with the teams involved was crucial for the 
identification of the resources devoted to each activity, and of the rationale to 
discriminate operational and research-driven features of the trial period. Second, recall 
bias on the part of project staff had the potential to interfere with the accuracy of our 
assessment. However, we feel the adoption of a micro-costing approach yielded a very 
accurate assessment of resources used for the trial and initial phase of the scale-up. In 
addition, triangulation of data sources was used to check consistency, including multiple 
members of staff asked to relate the process of the intervention, the same pieces of 
information being collected from different individuals, and the information that individuals 
reported being checked against financial records where relevant. 
 
Cost-effective interventions for the prevention of IPV in resource-poor settings are 
critically important, yet the evidence base to facilitate policy and program development 
remains at an early stage. This study indicates that coupling financial services to skills 
building and education may provide an important opportunity for addressing IPV. 
Emerging evidence from the microfinance sector suggests such integrated approaches 
may lead to additional health benefits – including improvements in breast-feeding, 
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diarrhoea management, immunisation rates, and the nutritional status of children 28-30 31-
34. This study suggests that proven development initiatives such as microfinance 
represent ideal opportunities for such value-adding public health interventions and that 
some form of public subsidy to support and strengthen these is warranted. 
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 Table 1: Transforming IPV-free year gained to DALYs 
 
 
1. Absolute number of DALYs lost to IPV in South Africa15 
 
319,135 
 
2. Population females >15 years13 
 
18,784,600 
 
3. Prevalence of women >15 years reporting IPV in past 12 months15 
 
18.4% 
 
4. Number of women >15 years reporting IPV in past 12 months in South 
Africa (2x3) 
 
3,456,366 
 
5. DALY loss / woman experiencing IPV past 12 months (1/4) 
 
0.0923 
 
 
 14
Table 2: Estimates burden attributable to IPV, South Africa 2000 (source: Norman 
et al 15) 
 
 
Sequelae 
 
DALYS lost 
Unipolar depressive disorders 42,097 
Anxiety disorders 12,140 
Alcohol abuse 17,704 
Drug use disorders 3,096 
Self-inflicted injuries  11,112 
Tobacco smoking 34,458 
Cervical cancer 8,460 
HIV/AIDs 97,591 
Sexually transmitted infections 6,194 
Intimate femicides  51,833 
Physical injuries 25,799 
Falls 3,090 
Other unintentional injuries 5,560 
Total 319,135 
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 Table 3:  Development costs  
 
 
Training costs at commencement of trial  
 
$ 
 Buildings  918 
 Equipment  861 
 Consultancies (non-recurrent)  21,031 
 Vehicles  6,181 
  
 Personnel  26,311 
 Supplies  419 
 Transport  3,528 
 Vehicle operating and maintenance  1,568 
 Building operating and maintenance  338 
 
Total Costs 
 
61,155 
 
Annuitised training costs - trial     
 
26,707 
 
Training materials development 
 
 Buildings  62 
 Equipment  65 
 Consultancies (non-recurrent)  11,657 
 Vehicles  215 
  
 Personnel  1,581 
 Supplies  28 
 Transport  201 
 Vehicle operating and maintenance  54 
 Building operating and maintenance  14 
 
 Total Costs  
 
13,877 
 
Annuitised training materials development costs 
 
3,254 
 
Training costs at commencement of scale-up 
 
 Personnel  51,507 
 Supplies  252 
 Transport  4,913 
 Vehicle operating and maintenance  825 
 Building operating and maintenance  167 
  
Total Costs  
 
57,663 
 
Annuitised training costs – scale-up     
 
13,520 
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Table 4: Cost-effectiveness estimates of trial and scale-up operations 
 
 
Costs 
 
Trial 
 
Scale-up 
 
Buildings 
 
$110 
 
$110 
 
Equipment 
 
$115 
 
$115 
 
Vehicles 
 
$150 
 
$3,281 
 
Development costs c 
     Training - trial    
 
 
$26,707 
 
  
$26,707 
  
      Manuals 
 
$3,254 
 
$3,254 
 
      Training – scale-up 
  
$13,520 
 
Operational staffd 
 
$5,429 
 
 
 
Suppliesd 
 
$52 
 
 
Transportd 
 
$425 
 
 
Vehicle operating and maintenanced 
 
$37 
 
 
Building operating and maintenanced 
 
$32 
 
 
TOTAL COSTS 
 
$36,706 
 
$33,467 
 
Per Capita Cost 
 
$43 
 
$13 
 
Baseline risk of IPV in previous 12 months 
 
11% 
 
11% 
 
Relative risk reduction (effect estimate from trial) 
 
55% 
 
55% 
 
Absolute risk reduction  
 
6.05% 
 
6.05% 
 
Cost per woman with an IPV–free year gained  
 
$711 
 
$213 
 
DALY loss / woman experiencing IPV past 12 monthse  
 
0.0923 
 
0.0923 
 
Cost per DALY gained 
 
$7,700 
 
$2,307 
 
 
                                                 
c See table 3 
d These were costs involved in establishing the operations (as opposed to the development and 
training) and  incurred only the trial phase  
e See table 1 
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Table 5: Sensitivity analysis – cost per DALY gained 
 
 
Parameter 
 
Trial 
$ 
 
Scale-up 
$ 
 
Upper bound 77% relative risk reduction  5,500 1,648 
 
Low bound 9% relative risk reduction 47,058 14,099 
   
Expected life (5 yrs; 5 yrs) 
 
Expected life (10yrs; 10 yrs) 
 
Discount rate 0% 
 
Discount rate 6% 
8,193 
 
5,015 
 
7,053 
 
8,184 
2,501 
 
1,454 
 
2,119 
 
2,437 
   
 
 
 
 
 
